semaglutide patent date Semaglutide's expires today. What does it mean for patients, pharma players and Novo Nordisk? The upcoming expiry of the

The SURMOUNT-1 trial, published in the New England Journal of Medicine, studied tirzepatide - the dual GLP-1 and GIP agonist - in adults with obesity or overweight with at least one weight-related condition over 72 weeks

Research has found that the GLP-1R is most abundantly expressed in the hypothalamus, the brain stem and the septal nucleus, where mRNA expression is also seen

By May 31, 2026, the FDA said it had received about 990 reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide, and it urged health care professionals and patients to send problems to the MedWatch system, per the agency

GLP-1 medicines can also influence your risk of certain health conditions, not just type 2 diabetes and obesity

doi: 10.1080/19490976.2021.1987782 23 KotloKAnbazhaganANPriyamvadaSJayawardenaDKumarAChenYet al